Table 2. Proportion of adverse skeletal related events (SREs), relative risks (RRs) and 95% confidence intervals (CIs) associated with SREs or death.

			Time to first SRE			Time to death
	Proportion SREs	P-value	RRs	95% CI	P-value	RRs	95% CI	P-value
Performance status
0–1	47/135 (34.8%)	0.18	2.07	1.3–3.28	0.002	1.65	1.20–2.70	0.002
>1	29/65 (44.6%)
Gleason score
<8	38/95 (40.0%)	0.59	1.03	0.60–1.80	0.90	1.31	1.07–1.62	0.01
⩾8	38/101 (37.6%)
PSA (ng ml −1 )
⩽118	37/100 (37.0%)	0.79	1.37	0.87–2.15	0.18	1.42	1.05–1.93	0.02
>118	38/98 (38.7%)
Hb (g dl −1 )
⩽12.5	38/89 (42.7%)	0.66	0.89	0.56–1.42	0.63	0.61	0.43–0.88	0.003
>12.5	38/93 (40.8%)
Albumin (g dl −1 )
⩽3.6	34/90 (37.7%)	0.66	0.85	0.53–1.36	0.49	0.64	0.46–0.88	0.007
>3.6	34/83 (40.9%)
LDH (U l −1 )
⩽405	32/75 (42.6%)	0.62	1.21	0.73–2.01	0.46	1.61	1.13–2.28	0.008
>405	29/75 (38.6%)
Types of bone lesions
Lytic/mixed	25/56 (44.6%)	0.28	0.85	0.53–1.36	0.50	1.00	0.72–1.41	0.97
Blastic	51/134 (38.1%)
Disease extent in bone
⩽6 sites	28/94 (29.8%)	0.015	2.41	1.50–3.88	0.0001	1.47	1.08–2.01	0.014
>6 sites	48/103 (46.6%)
Bone pain
Pain score <5	31/105 (29.5%)	0.011	1.94	1.44–2.63	0.0001	1.53	1.27–1.85	0.0001
Pain score ⩾5	44/95 (45.8%)
ALP (U l −1 )
⩽165	29/94 (30.8%)	0.014	2.50	1.56–4.02	0.0001	1.71	1.25–2.35	0.001
>165	45/93 (48.4%)
NTx (nmol mmol−1 creatinine)
⩽96	10/50 (20.0%)	0.001	3.10	1.47–6.54	0.001	1.37	0.90–2.06	0.14
>96	31/53 (58.5%)
Ca (mmol l −1 )
⩽2.35	38/92 (41.3%)	0.65	0.64	0.35–1.17	0.15	1.10	0.80–1.51	0.54
>2.35	35/92 (38.0%)
Duration of androgen deprivation therapy (months)
⩽24.4	41/94 (43.6%)	0.37	0.65	0.41–1.02	0.06	0.74	0.54–1.01	0.05
>24.4	35/94 (37.2%)